Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis

R. Wilson, T. Welte, E. Polverino, A. De Soyza, H. W. Greville, A. E. O‘Donnell, J. Alder, P. Reimnitz, B. Hampel (London, Newcastle upon Tyne, United Kingdom; Hannover, Wuppertal, Berlin, Germany; Barcelona, Spain; Adelaide, Australia; Washington, Montville, United States Of America)

Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Session: Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Session type: Oral Presentation
Number: 1929
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Wilson, T. Welte, E. Polverino, A. De Soyza, H. W. Greville, A. E. O‘Donnell, J. Alder, P. Reimnitz, B. Hampel (London, Newcastle upon Tyne, United Kingdom; Hannover, Wuppertal, Berlin, Germany; Barcelona, Spain; Adelaide, Australia; Washington, Montville, United States Of America). Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. Eur Respir J 2011; 38: Suppl. 55, 1929

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011

Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016


Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011

In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016


Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
Source: Eur Respir Rev 2013; 22: 476-486
Year: 2013



Safety and pharmacokinetics of multiple-dose ciprofloxacin dry powder for inhalation in patients with moderate or severe COPD
Source: Annual Congress 2011 - Role of infection in exacerbations of COPD
Year: 2011

Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Year: 2012


Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study
Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy
Year: 2020




Effects of long term low dose azithromycin in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections
Year: 2010

Long-term administration of aerosolised tobramycin in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 619s
Year: 2005

Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013


Effect of short-term inhalation of warm saline atomised gas on patients with non-cystic fibrosis bronchiectasis
Source: ERJ Open Res, 6 (1) 00130-2019; 10.1183/23120541.00130-2019
Year: 2020



Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study
Source: Eur Respir J 2011; 38: 1071-1080
Year: 2011



Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD
Source: Annual Congress 2012 - Hot topics in respiratory infections
Year: 2012



Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007


Distribution of nebulised gentamicin in patients with bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 640s
Year: 2004

Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001

Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Source: Eur Respir J 2002; 19: 303-309
Year: 2002



Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis
Source: Eur Respir J 2007; 30: Suppl. 51, 528s
Year: 2007